- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Glycogen Storage Disease Type I in United Kingdom
Total 29138 results
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPompe DiseaseUnited States
-
University of FloridaCompletedPompe DiseaseUnited States
-
Duke UniversitySanofiRecruiting
-
Duke UniversityGenzyme, a Sanofi CompanyRecruitingPompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
University of California, IrvineGenzyme, a Sanofi CompanyCompletedPompe DiseaseUnited States
-
Amicus TherapeuticsTerminated
-
University of FloridaTerminated
-
O & O Alpan LLCCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Serhat Gumrukcu, MD PhDFrida Therapeutics LLCRecruiting
-
Duke UniversityCompleted
-
Duke UniversityGenzyme, a Sanofi CompanyCompleted
-
Duke UniversityCompletedPompe DiseaseUnited States
-
Duke UniversityCompleted
-
Dwight Koeberl, M.D., Ph.D.Completed
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of FloridaLacerta TherapeuticsCompletedPompe DiseaseUnited States
-
University of FloridaBioMarin PharmaceuticalCompleted
-
Asklepios Biopharmaceutical, Inc.Active, not recruiting
-
Amicus TherapeuticsRecruitingPompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Netherlands
-
Genzyme, a Sanofi CompanyCompleted
-
Duke UniversityGenzyme, a Sanofi CompanyActive, not recruitingPompe Disease (Late-onset) | Pompe Disease | GAA DeficiencyUnited States
-
Duke UniversityWithdrawnPompe Disease (Late-onset)United States
-
Amicus TherapeuticsCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Duke UniversityCompleted
-
Amicus TherapeuticsAvailablePompe Disease Infantile-OnsetTaiwan, United States, Italy
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Germany, Israel, Italy, Netherlands, Taiwan
-
Duke UniversityCompleted
-
Genzyme, a Sanofi CompanyTerminatedPompe DiseaseUnited States
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe Disease Infantile-OnsetUnited States, France, South Africa
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Astellas Gene TherapiesRecruitingPompe Disease (Late-onset)United States, France, Spain, Taiwan
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Glycogenosis 2United States
-
Genzyme, a Sanofi CompanyRecruitingGlycogen Storage Disease Type II | Pompe DiseaseHungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
-
Amicus TherapeuticsRecruitingPompe Disease (Late-onset)United States, Taiwan, Japan, Australia, Canada
-
Oxford University Hospitals NHS TrustUniversity of Oxford; Barts & The London NHS Trust; Ninewells HospitalCompletedMelanoma Stage III | Melanoma, Stage II | Melanoma, Stage IUnited Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe DiseaseBelgium, United States, Czechia, Germany, Italy, Taiwan
-
Amicus TherapeuticsTerminatedLate-onset Pompe DiseaseUnited States, Canada, Australia, Belgium
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
University of California, IrvineCompletedMuscle Weakness | Pompe DiseaseUnited States
-
Duke UniversityGenzyme, a Sanofi CompanyRecruitingLate-Onset Pompe Disease | Lysosomal DiseaseUnited States
-
Cambridge University Hospitals NHS Foundation TrustMedical Research Council; National Institute for Health Research, United KingdomRecruitingGaucher Disease, Type III | Gaucher Disease, Type IUnited Kingdom